Please assess the completion status of the following clinical trial:

Trial Title: Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Is not of reproductive potential, or is of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner while receiving trial medication or within 6 months after the last dose of trial medication~* Has chronic back pain of ≥3 months duration by history~* Has physician-diagnosed active non-radiographic axial spondyloarthritis (nr-axSpA) with disease duration \<= 5 years~* Meets one of the following criteria:~  1. Has active inflammation on magnetic resonance imaging (MRI) highly suggestive of sacroiliitis associated with spondyloarthropathy and 1 or more of the following spondyloarthritis (SpA) characteristics:~     * Inflammatory back pain~    * Arthritis (physician-diagnosed)~    * Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia)~    * Dactylitis (physician-diagnosed)~    * Psoriasis (physician-diagnosed)~    * History of physician-diagnosed inflammatory bowel disease (IBD)~    * History of uveitis confirmed by an ophthalmologist~    * Good response to nonsteroidal anti-inflammatory drugs (NSAID)~    * Family history of SpA (presence of ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD)~    * Elevated C-reactive protein (CRP)~       * Human leukocyte antigen B27 (HLA-B27)+ gene OR~ 2. Has a HLA-B27+ gene and 2 or more of the following SpA characteristics:~     * Inflammatory back pain~    * Arthritis (physician-diagnosed)~    * Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia)~    * Dactylitis (physician-diagnosed)~    * Psoriasis (physician-diagnosed)~    * History of physician-diagnosed inflammatory bowel disease (IBD)~    * History of uveitis confirmed by an ophthalmologist~    * Good response to nonsteroidal anti-inflammatory drugs (NSAID)~    * Family history of SpA (presence of ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD)~    * Elevated C-reactive protein (CRP)~* Has elevated CRP at Screening or evidence of active inflammation in the sacroiliac joints on MRI~* Has an Ankylosing Spondylitis Disease Activity Score (ASDAS) \>= 2.1 at Screening~* Shows high disease activity at Screening and Baseline of both a Total Back Pain score of ≥4 and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of \>= 4~* Has an acceptable history of NSAID use~* Has no history of untreated latent or active tuberculosis (TB) prior to Screening~* Has had no recent close contact with a person with active TB or, if there has been such contact, will undergo additional evaluations and receive appropriate treatment for latent TB~* Agrees to undergo screening for hepatitis B virus (HBV) and demonstrates negative results for hepatitis B surface antigen (HBsAg) and HBV deoxyribonucleic acid (DNA)~Exclusion Criteria:~* Has bilateral sacroiliitis Grade 2 or unilateral sacroiliitis Grade 3 or Grade 4 on conventional x-rays~* Is a nursing or pregnant female, or intends to become pregnant within 6 months after receiving trial medication~* Intends to donate eggs (female participants) or sperm (male participants) while receiving trial medication or within 6 months after trial medication~* Has any clinically significant condition or situation that would interfere with the trial evaluations or participation in the trial~* Has ever received any cytotoxic drugs, including chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents~* Has received any treatment listed below more recently than the indicated off-drug period prior to Screening~  * • Disease-modifying anti-rheumatic drugs (30 days off drug)~ * • Live vaccinations (3 months off drug)~ * • Investigational medications (30 days or 5 half-lives off drug, whichever is longer)~ * • Bacille Calmette-Guerin (BCG) vaccination (12 months off drug)~* Has any systemic inflammatory condition, including psoriatic arthritis, active Lyme disease, systemic lupus erythematosus, infectious arthritis, vasculitis, parvovirus infection, rheumatoid arthritis, active uveitis, or active IBD~* Has a history of latent or active granulomatous infection prior to Screening~* Had a nontuberculous mycobacterial infection or opportunistic infection within 6 months prior to Screening~* Has a history of an infected joint prosthesis, or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced~* Had a serious infection, has been hospitalized for an infection, or has been treated with IV antibiotics for an infection within 2 months prior to Baseline~* Had a history of, or ongoing, chronic or recurrent infectious disease~* Is known to be infected with human immunodeficiency virus (HIV) or seropositive for hepatitis C virus (HCV)~* Has had a chest x-ray within 2 months prior to Screening that shows an abnormality suggestive of a current active infection or malignancy~* Has a history of lymphoproliferative disease~* Has had a malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured)~* Has a history of known demyelinating diseases such as multiple sclerosis or optic neuritis~* Has a history of or concurrent congestive heart failure of any grade~* Has a transplanted organ (with the exception of a corneal transplant performed \>= 3 months prior to baseline)~* Has current signs or symptoms of significant medical illness which could interfere with the trial, or require treatment that might interfere with the trial~* Is a user of recreational or illicit drugs or has or had a substance abuse (drug or alcohol) problem within the previous 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- GLM SC QM (Full Treatment Regimen) (Type: EXPERIMENTAL): Period 1: participants are treated with open-label (OL) GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded SC GLM QM for up to 12 months
- GLM SC Q2M (Reduced Treatment Regimen) (Type: EXPERIMENTAL): Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded GLM SC every other month alternating with matching placebo to GLM every other month for up to 12 months
- Placebo (Treatment Withdrawal Regimen) (Type: PLACEBO_COMPARATOR): Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded placebo for up to 12 months
- OL GLM Retreatment (Type: EXPERIMENTAL): Participants who experience a disease flare during double-blinded treatment in Period 2 will discontinue blinded treatment and receive OL GLM SC QM.

Based on this trial design, predict the completion outcome and termination type (if applicable).